These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34315093)

  • 1. Deregulated glutamate to pro-collagen conversion is associated with adverse outcome in lung cancer and may be targeted by renin-angiotensin-aldosterone system (RAS) inhibition.
    Kocher F; Tymoszuk P; Amann A; Sprung S; Salcher S; Daum S; Haybaeck J; Rinnerthaler G; Huemer F; Kauffmann-Guerrero D; Tufman A; Seeber A; Wolf D; Pircher A
    Lung Cancer; 2021 Sep; 159():84-95. PubMed ID: 34315093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Renin-angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients.
    Tozuka T; Yanagitani N; Yoshida H; Manabe R; Ogusu S; Tsugitomi R; Sakamoto H; Amino Y; Ariyasu R; Uchibori K; Kitazono S; Seike M; Gemma A; Nishio M
    Anticancer Res; 2021 Apr; 41(4):2093-2100. PubMed ID: 33813419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detrimental effect of renin-angiotensin blockade on progression of chronic kidney disease at later stages: A matter of dosage adjustment?
    Caravaca-Fontán F; Valladares J; Díaz-Campillejo R; Barroso S; Luna E; Caravaca F
    Nefrologia (Engl Ed); 2020; 40(1):38-45. PubMed ID: 31196659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients receiving bevacizumab.
    Nihei S; Sato J; Harada T; Kuyama S; Suzuki T; Waga N; Saito Y; Kisara S; Yokota A; Okada K; Tsuchiya M; Terui K; Tadokoro Y; Chiba T; Kudo K; Oizumi S; Inoue A; Morikawa N
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1051-1059. PubMed ID: 29651572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Renin-angiotensin System Blockade Improved Short-term and Longterm Renal Outcomes in Systemic Lupus Erythematosus Patients with Antiphospholipid-associated Nephropathy.
    Yue C; Li G; Wen Y; Li X; Gao R
    J Rheumatol; 2018 May; 45(5):655-662. PubMed ID: 29449503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D levels condition the outcome benefits of renin-angiotensin system inhibitors (RASI) among patients undergoing percutaneous coronary intervention.
    Verdoia M; Nardin M; Rolla R; Negro F; Gioscia R; Saghir Afifeh AM; Viglione F; Suryapranata H; Marcolongo M; De Luca G;
    Pharmacol Res; 2020 Oct; 160():105158. PubMed ID: 32841717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of renin angiotensin system inhibitors on homocysteine levels and platelets reactivity in patients on dual antiplatelet therapy.
    Nardin M; Verdoia M; Gioscia R; Negro F; De Luca G
    Nutr Metab Cardiovasc Dis; 2021 Apr; 31(4):1276-1285. PubMed ID: 33549433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is the use of renin-angiotensin system inhibitors in patients with aortic valve stenosis safe and of prognostic benefit? A systematic review and meta-analysis.
    Andersson C; Abdulla J
    Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):21-27. PubMed ID: 27615013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The beneficial effects of renin-angiotensin system inhibitors (RASI) on IgA nephropathy with tubulointerstitial lesions categorized by Oxford classification.
    Kamiyama T; Moriyama T; Kumon S; Karasawa K; Nitta K
    Clin Exp Nephrol; 2019 Jun; 23(6):834-840. PubMed ID: 30796546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renin-angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis.
    Bang CN; Greve AM; Køber L; Rossebø AB; Ray S; Boman K; Nienaber CA; Devereux RB; Wachtell K
    Int J Cardiol; 2014 Aug; 175(3):492-8. PubMed ID: 25012498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonism of the renin-angiotensin-aldosterone system and collagen metabolism in cardiac fibroblasts.
    Lijnen P; Petrov V
    Methods Find Exp Clin Pharmacol; 1999 Apr; 21(3):215-27. PubMed ID: 10389125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of intracardiac renin-angiotensin-aldosterone system in extracellular matrix remodeling.
    Lijnen PJ; Petrov VV
    Methods Find Exp Clin Pharmacol; 2003 Sep; 25(7):541-64. PubMed ID: 14571285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of renin angiotensin system inhibitors in patients with chronic kidney disease.
    Adam WR; Wright JR
    Intern Med J; 2016 May; 46(5):626-30. PubMed ID: 27170242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.
    Pinter M; Weinmann A; Wörns MA; Hucke F; Bota S; Marquardt JU; Duda DG; Jain RK; Galle PR; Trauner M; Peck-Radosavljevic M; Sieghart W
    United European Gastroenterol J; 2017 Nov; 5(7):987-996. PubMed ID: 29163965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study.
    Savarese G; Dahlström U; Vasko P; Pitt B; Lund LH
    Eur Heart J; 2018 Dec; 39(48):4257-4265. PubMed ID: 30351407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the renin-angiotensin system inhibitors in malignancy: a review.
    Yang J; Yang X; Gao L; Zhang J; Yi C; Huang Y
    Am J Cancer Res; 2021; 11(3):884-897. PubMed ID: 33791161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.
    Pinter M; Jain RK
    Sci Transl Med; 2017 Oct; 9(410):. PubMed ID: 28978752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical applicability of renin-angiotensin system inhibitors in cancer treatment.
    Jiang H; Tai Z; Chen Z; Zhu Q; Bao L
    Am J Cancer Res; 2021; 11(2):318-336. PubMed ID: 33575074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin-angiotensin-aldosterone system inhibition decreased contrast-associated acute kidney injury in chronic kidney disease patients.
    Chen YT; Chan CK; Li WY; Huang TM; Lai TS; Wu VC; Chu TS;
    J Formos Med Assoc; 2021 Jan; 120(1 Pt 3):641-650. PubMed ID: 32762878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual renin-angiotensin system blockade and outcome benefits in hypertension: a narrative review.
    Mann JF; Böhm M
    Curr Opin Cardiol; 2015 Jul; 30(4):373-7. PubMed ID: 26049384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.